Methods This was a phase 3 double-blind trial of the RTS, S/AS01 vaccine which is directed
against the pre-erythrocytic stage of Plasmodium falciparum malaria. It was conducted in 11 …

Background The candidate malaria vaccine RTS, S/AS01 reduced episodes of both clinical
and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing …

RTS, S is the world's most advanced malaria vaccine candidate and is intended to protect
infants and young children living in malaria endemic areas of sub‐Saharan Africa against …

Abstract Background GlaxoSmithKline Biologicals and the PATH Malaria Vaccine Initiative
are working in partnership to develop a malaria vaccine to protect infants and children living …

Methods In this phase III double-blind trial, 6537 infants (aged 6–12 weeks) and 8922
children (aged 5–17 months) were enrolled at 11 centres in seven countries, from 2009 to …

Summary Background RTS, S/AS02A is a pre-erythrocytic stage malaria vaccine that
provides partial protection against infection in malaria-naive adult volunteers and …

A primary concern for the RTS, S malaria vaccine candidate is duration of protection. The
ongoing Phase III trial reported evidence of waning efficacy within the first year following …

Background The efficacy and safety of the RTS, S/AS01 candidate malaria vaccine during
18 months of follow-up have been published previously. Herein, we report the final results …

Summary Background The RTS, S/AS01 E candidate malaria vaccine is being developed for
immunisation of infants in Africa through the expanded programme on immunisation (EPI). 8 …

BACKGROUND: An ongoing phase 3 study of the efficacy, safety, and immunogenicity of
candidate malaria vaccine RTS, S/AS01 is being conducted in seven African countries …